At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free at a median follow-up of 4.0 years

Independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes

Independent study showed 92.9% reduction in fibroadenoma volume at 12 months post-treatment with ProSense®

FDA clearance of ProSense® in early-stage breast cancer drives expanding global adoption and clinical interest in breast cryoablation

CAESAREA, Israel, May 19, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that cryoablation and ProSense® were featured at the annual European Conference on Interventional Oncology ("ECIO") 2026, held in Basel, Switzerland on April 26 to 30, 2026.